Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of
acute venous thromboembolism. This study sought to evaluate the efficacy and safety of …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

Conclusions A fixed-dose regimen of apixaban was not inferior to conventional therapy for
treatment of acute venous thromboembolism (VTE), with less risk of bleeding. Summary …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Background Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a
prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

Following major orthopaedic surgery, guidelines usually recommend continued
thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant …